Dabigatran Potentiates Gemcitabine-Induced Growth Inhibition of Pancreatic Cancer in Mice
- 62 Downloads
Pancreatic cancer is one of the most lethal solid malignancies, with few treatment options. We have recently shown that expression of protease activated receptor (PAR)-1 in the tumor microenvironment drives the progression and induces the chemoresistance of pancreatic cancer. As thrombin is the prototypical PAR-1 agonist, here we address the effects of the direct thrombin inhibitor dabigatran on pancreatic cancer growth and drug resistance in an orthotropic pancreatic cancer model. We show that dabigatran treatment did not affect primary tumor growth, whereas it significantly increased tumor dissemination throughout the peritoneal cavity. Increased dissemination was accompanied by intratumoral bleeding and increased numbers of aberrant and/or collapsed blood vessels in the primary tumors. In combination with gemcitabine, dabigatran treatment limited primary tumor growth, did not induce bleeding complications and prevented tumor cell dissemination. Dabigatran was, however, not as efficient as genetic ablation of PAR-1 in our previous study, suggesting that thrombin is not the main PAR-1 agonist in the setting of pancreatic cancer. Overall, we show that dabigatran potentiates gemcitabine-induced growth inhibition of pancreatic cancer but does not affect primary tumor growth when used as monotherapy.
Pancreatic ductal adenocarcinoma is one of the most lethal solid malignancies and is associated with a high propensity for local invasion and distant metastases (1). Despite improvements in the treatment of cancer in general, the overall 5-year survival rate of pancreatic cancer remains less than 5% (2) and overall mortality approaches 99% (3). The high mortality results from the majority of patients presenting with locally advanced and/or metastatic disease, which is rapidly progressive and inevitably fatal. Less than 20% of patients undergo surgical resection, which is associated with improved 5-year survival rates of around 15–20%. However, the majority of this selected group of patients eventually also succumb to metastatic disease (4).
Protease activated receptor (PAR)-1 (also known as coagulation factor II receptor) is a seven-transmembrane G-coupled receptor that is activated by proteolytic cleavage of the N-terminal extracellular region, thereby releasing a novel tethered ligand that interacts with the body of the receptor to induce transmembrane signaling (5). Expression levels of PAR-1 are increased in several cancer types, such as breast and lung cancer (6, 7, 8). Moreover, these increased PAR-1 levels are associated with disease progression and reduced overall survival in breast and lung cancer patients (9,10).
Recently, we showed that genetic ablation of PAR-1 from the pancreatic tumor microenvironment limited tumor growth and metastasis in a murine orthotopic pancreatic cancer model (11). Indeed, both tumor volume and weight were reduced around 50% in PAR-1-deficient mice as compared with wild-type mice, whereas the percentage of mice with metastasis in distant organs was reduced from 100% in wild-type mice to 12.5% in PAR-1-deficient mice. Even more strikingly, PAR-1 deficiency potentiated gemcitabine-induced tumor regression and completely abolished tumor growth in six out of eight mice.
Thrombin, the central enzyme in the coagulation cascade, is the prototypical PAR-1 agonist (12,13), and it is thus tempting to speculate that thrombin is a key driver in pancreatic cancer growth, metastasis and drug resistance. The potential importance of thrombin in pancreatic cancer is underscored by the fact that pancreatic cancer is frequently associated with thrombotic complications, suggesting that thrombin levels are high in pancreatic cancer patients. Moreover, thrombin induces pancreatic tumor growth and invasion in in vitro model systems (14).
Dabigatran etexilate, the pro-drug of dabigatran, is a peptidomimetic reversible and competitive direct thrombin inhibitor (15, 16, 17, 18) used in clinics for the prevention of venous thromboembolism after elective hip or knee arthroplasty and stroke in patients with atrial fibrillation (19, 20, 21, 22). In the current study, we employed dabigatran etexilate in an orthotopic pancreatic cancer model to challenge the importance of thrombin in pancreatic cancer growth and drug resistance, and we hypothesized that dabigatran would potentiate gemcitabine-induced growth inhibition of pancreatic tumors.
Materials and Methods
Eight-week-old wild-type C57Bl/6 mice (32 mice in total) were purchased from Charles River. All mice were maintained according to institutional guidelines. Animal procedures were carried out in compliance with the Institutional Standards for Humane Care and Use of Laboratory Animals. The Animal Care and Use Committee of the Academic Medical Center (Amsterdam, the Netherlands) approved all experiments (permit no. DIX102046). Four groups with eight mice per group were used in the experiment.
Cell Culture and Cell Lines
Murine pancreatic cancer cells (Panc02; kindly provided by Dr. Schmitz, Universitätsklinikum Bonn) were maintained at 5% CO2 and 37±C in Roswell Park Memorial Institute medium 1640 (Invitrogen) supplemented with 10% fetal bovine serum (FBS); Lonza), 1% penicillin-streptomycin and 1% L-glutamine (Lonza). Tumor-associated fibroblasts were isolated from a patient-derived xenograft and grown in Iscove’s Modified Dulbecco’s Medium (Lonza, BioWhittaker) supplemented with 10% FBS, 1% penicillin-streptomycin and 1% L-glutamine.
Tumor-associated fibroblasts were serum starved for 2 h, after which they were stimulated with thrombin (1 U/mL) or saline. After 24 h, medium was collected, sterilized through a 0.2 µm filter and stored at −20±C.
Orthotopic Pancreatic Cancer Model
Mice were subjected to an orthotopic model of pancreatic cancer essentially as previously described (23,24). Briefly, confluent cultures of Panc02 cells were detached by TrypLE™ Select (Invitrogen) and pelleted at 340 g for 5 min, washed twice in phosphate-buffered saline (PBS) and resuspended in PBS. Tumor cells (4 × 105 in 50 µL PBS) were injected directly into the tail of the pancreas under anesthesia. Dabigatran (BIBR1048, at a dose of 80 mg/kg in 0.5% Natrosol solution, as suggested by the manufacturer and shown to be well tolerated in mice [25, 26, 27, 28]) or 0.5% Natrosol solution (placebo control) was administered by oral gavage twice daily starting from 7 d after tumor cell injection. If indicated, mice were treated with gemcitabine (100 mg/kg in PBS, intraperitoneal) or PBS (control) starting from 7 d after tumor cell injection, and this treatment was repeated twice weekly. Mice were evaluated for changes in body weight and signs of discomfort or morbidity, and they were euthanized 3 or 5 (gemcitabine experiment) wks after tumor cell injection.
Histological examination was performed essentially as previously described (29,30). Briefly, the excised tumor was fixed in formalin, embedded in paraffin and 4 µm thick slides were subsequently deparaffinized, rehydrated and washed in deionized water. Slides were stained with hematoxylin and eosin (H&E) according to routine procedures. For immunohistochemistry of Ki67, F4/80 (also known as EGF-like module-containing mucin-like hormone receptor-like 1), arginase 1 (Arg1), α-smooth muscle actin (α-SMA) and cluster of differentiation 31 (CD31; also known as platelet endothelial cell adhesion molecule), endogenous peroxidase activity was quenched with 0.3% hydrogen peroxide in methanol for 15 or 20 (F4/80) min at room temperature, and antigen retrieval was performed for 10 min (Ki67, α-SMA and CD31) or 20 min (F4/80 and Arg1) at 96±C in 10 mM sodium citrate buffer, pH 6.0. Next, slides were blocked for 15 min with Ultra V block (Thermo Scientific) or (for α-SMA) 30 min with 5% normal goat serum. Primary antibodies against Ki67 (1:500, clone Sp6; Neomarkers), Arg1 (1:2000, a gift from Prof W Lamers), F4/80 (1:400, clone:CI:A3-1; Serotec) or α-SMA (1:800, clone 1A4; Santa Cruz) were incubated overnight at 4±C. For CD31, the primary antibody (1:1000; sc-1506-R; Santa Cruz Biotechnology) was incubated for 90 min at room temperature. Slides were subsequently incubated with appropriate horseradish peroxidase-conjugated secondary antibodies, and 3,3’-diaminobenzidine staining was used to visualize peroxidase activity. Slides were photographed with a microscope equipped with a digital camera (Leica CTR500, Leica Microsystems). CD31-positive vessels were counted in 10 different fields per slide at 400 × magnification. F4/80, Arg1, Ki67 and α-SMA staining was analyzed with ImageJ and expressed as percentage of surface area. Depending on tumor size, an average of 10 to 30 pictures (random field) at 200 × magnification per tumor were used for analysis.
Cell Viability and Proliferation
Cell viability was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphen-yltetrazolium bromide reduction assays as previously described (11). Cell proliferation was measured using a cell proliferation enzyme-linked immunosorbent assay 5-bromo-2′-deoxyuridine (Roche) as previously described (31).
Results are presented as means ± standard error of the mean. Differences between multiple groups were analyzed by two-way analysis of variance and/or Tukey t test using GraphPad Prism with P < .05 considered significant (*P < .05; **P < .001 and ***P < .0001).
All supplementary materials are available online at https://doi.org/www.molmed.org.
Influence of Dabigatran on Pancreatic Cancer Growth and Tumor Cell Dissemination
Combination Therapy of Dabigatran and Gemcitabine in Pancreatic Cancer
Effect of Dabigatran on Macrophage Recruitment and Fibroblast Activation in Pancreatic Cancers
Drug resistance of pancreatic cancer also has been suggested to rely on the desmoplastic reaction (22,33) and cancer-associated fibroblasts promote tumor progression (34). As thrombin is a key factor in fibroproliferative disease (35), thrombin-driven fibroblast activation may explain the differences seen in gemcitabine efficiency. As shown in Figure 5C, however, the number of matrix-producing αSMA-positive fibroblasts is not different in dabigatran-treated or control mice.
Gemcitabine Sensitivity of Panc02 Cells In Vitro
We previously showed that PAR-1 deficiency in the pancreatic tumor microenvironment limits tumor growth and potentiates gemcitabine-induced tumor regression in an orthotopic pancreatic cancer model (11). In the current manuscript, we address the importance of thrombin, the prototypical PAR-1 agonist, in pancreatic cancer growth and drug resistance using a similar orthotopic model. We show that thrombin inhibition by dabigatran has no effect on the primary tumor when administered as single treatment. However, dabigatran does potentiate gemcitabine cytotoxicity in pancreatic cancer.
Dabigatran treatment is clearly less effective in the setting of pancreatic cancer as compared with PAR-1 deficiency. Not only does dabigatran not affect tumor growth by itself, it also less efficiently potentiates gemcitabine activity. Indeed, gemcitabine treatment of PAR-1-deficient mice completely abolished tumor growth in 75% of the mice (11), whereas all dabigatran-treated mice showed pancreatic tumors (Figure 1) already at 3 wks. The most likely explanation for the limited effect of dabigatran may be that thrombin is not the main PAR-1 agonist in the setting of pancreatic cancer. Next to thrombin, several PAR-1 agonists, such as (among others) matrix metalloproteinase-1 (also known as interstitial collagenase) (36), prohibitins (37), granzyme K (38), kallikrein-related peptidase-4 (39) and serine protease 3 (also known as trypsin 3) (40) were recently identified. Serine protease 3 could be especially relevant, as it seems to play an important role in the progression, metastasis and prognosis of human pancreatic cancer (41). Alternatively, thrombin inhibition might not be as effective as PAR-1 deficiency, as drug delivery is notoriously difficult in pancreatic cancer (42). Finally, one could argue that the observed difference between stromal PAR-1 deficiency and dabigatran treatment could be due to the fact that dabigatran also targets thrombin-induced effects on tumor cells. However, thrombin is mainly considered a driver of tumor cell proliferation (43) and, in the setting of pancreatic cancer, enhances the adhesion of pancreatic cancer cells to the extracellular matrix and/or endothelium (14).
Dabigatran treatment is associated with increased numbers of blood vessels in primary tumors (Figure 2). This is somewhat puzzling, as thrombin is known to enhance angiogenesis (44), and anticoagulants inhibit tumor cell-mediated angiogenesis (45). Interestingly, however, low thrombin levels (i.e., 0.1–0.3 U/mL) more potently induce angiogenesis as compared with high (i.e., 1 U/mL) thrombin levels (46), suggesting that residual thrombin activity in dabigatran-treated mice might actually induce angiogenesis. In line, some studies do show that thrombin inhibits angiogenesis in vitro (47), whereas both FX and FXa possess anti-angiogenic properties in vitro in zebra fish intersegmental vasculature formation and in chick embryo chorioallantoic membrane assays (48).
We previously showed that macrophages play a key role in PAR-1-dependent drug resistance of pancreatic cancer (11). Dabigatran treatment, however, does not affect macrophage recruitment (Figure 5A, B) and thrombin-dependent drug resistance thus seems macrophage independent. Alternatively, tumor-associated fibroblasts could modify drug resistance (49, 50, 51) in a thrombin-dependent manner, although PAR-1 deficiency did not affect fibroblast numbers or drug sensitivity (11). Dabigatran treatment, however, did not modify the number of SMA-positive fibroblasts within the tumor (Figure 5C), nor did thrombin limit tumor-associated fibroblast-induced resistance in vitro (Figures 6A, B). Consequently, we hypothesize that dabigatran-induced proliferation, as evidenced by increased numbers of Ki67-positive cells (Figure 2C), explains the increased gemcitabine sensitivity (Figure 6D). Indeed, gemcitabine blocks DNA synthesis and is more effective on rapidly proliferating cells (52). In line, gemcitabine cytotoxicity is increased in highly proliferative Panc02 as compared with growth factor-depleted low-proliferative Panc02 cells (Figure 6C).
Tumor cell dissemination throughout the peritoneal cavity is increased in dabigatran-treated mice as compared with control mice (Figure 1). The increase of aberrant or collapsed vessels in tumors of dabigatran-treated mice combined with bleeding in these mice likely explains the increased dissemination. Importantly, dabigatran-induced bleeding seems specific for pancreatic cancer, as the dabigatran dose used (i.e., 80 mg/kg, twice daily) is well tolerated and did not induce bleeding in an ovarian cancer model (25), whereas long-term treatment with a dose of 140 mg/kg (administered via oral gavage) is safe and did not induce bleeding in models of allergic lung inflammation (26), high-fat-diet-induced fatty liver disease (27) and glial activation (28). Dabigatran-induced bleeding in our orthotopic pancreatic cancer model is probably due to the fact that orthotopically grown pancreatic tumors are already prone to bleed at end-stage disease when primary tumors are large (personal observation). Notably, combined gemcitabine/dabigatran treatment does not induce bleeding complications and results in reduced tumor cell dissemination.
Several clinical studies have evaluated the potential clinical efficacy of anticoagulants in pancreatic cancer patients. In a nonrandomized study, the addition of low-molecular-weight heparin (LMWH) to standard gemcitabine/cisplatinum chemotherapy significantly improved survival in patients with locally advanced or metastatic pancreatic carcinoma (53). The total response rate was almost 60% for patients treated with LMWH, compared with only 12% for patients treated with chemotherapy only. The response of pancreas cancer patients to LMWH treatment was confirmed in a retrospective analysis of patients who received chemotherapy for advanced pancreatic adenocarcinoma (54). The median survival of patients with metastatic disease increased from 3.8 to 6.6 months due to treatment. LMWH treatment had no significant effect on patients without metastatic disease (median survival of 10.3 and 8.3 months for LMWH-treated versus control patients). Contrary to this study suggesting that anticoagulants may increase the overall survival of pancreatic cancer patients, a recent randomized controlled clinical trial did not show any benefit of LMWH in pancreatic cancer patients (55). The clinical relevance of anticoagulants and the importance of thrombin in pancreatic cancer are therefore still under debate. The current study suggests that thrombin inhibition only limits pancreatic cancer progression in combination with gemcitabine, and it would be interesting to address whether such a relation also holds true in the randomized controlled clinical trial.
In the current manuscript, we employed an orthotopic pancreatic cancer model in which murine pancreatic cancer cells were grafted into the pancreases of immune-competent mice. This syngeneic orthotopic model offers tissue-specific pathology and is generally deemed more clinically relevant compared with xenograft models, in which human tumor cells are transplanted as xenografts into immunodeficient mice (56,57). As elegantly indicated in a recent review (58), murine models using human cells have shortcomings, such as harboring impaired immune infiltrates (e.g., lymphocytes, natural killer cells). This is particularly important, as a complex relationship exists between the immune system and pancreatic cancer development, and these complex interactions have important implications for disease progression and control (59,60). For example, CD8 + T cells and Th1-polarized CD4 + T cells mediate tumor protection in murine pancreatic cancer models and are associated with prolonged survival in humans (61,62). Likewise, blocking cytotoxic CD8 + anti-tumor responses by myeloidderived suppressor cells significantly accelerates pancreatic cancer growth (63). In contrast, antigen-restricted Th2-deviated CD4 + T cells strongly promote pancreatic cancer progression in mice (64). Accordingly, intratumoral CD4 + Th2 cell infiltrates correlate with reduced survival in human pancreatic cancer (61,62). Next to a dysfunctional immune system, xenografts using human cells possess certain aberrant cross-species ligand-receptor interactions (e.g., hepatocyte growth factor-c-mesenchymalepithelial transition) (65). Importantly, human-mouse species differences have also been described for interactions of coagulation factors (66), which suggests that murine xenografts may be preferred over human xenografts when targeting the coagulation cascade.
Dabigatran-dependent thrombin inhibition potentiates gemcitabineinduced growth inhibition and tumor cell dissemination of pancreatic cancer. In the absence of gemcitabine, however, dabigatran treatment led to intratumoral bleeding and consequent increased tumor cell dissemination.
The authors declare they have no competing interests as defined by Molecular Medicine or other interests that might be perceived to influence the results and discussion reported in this paper.
Dabigatran was kindly provided by Dr. Ashley Goss from the CardioMetabolic Disease Research department of Boehringer Ingelheim Pharmaceuticals. This study is supported by grants from the Dutch Cancer Foundation (2009–4324 and 2014–6782).
- 33.Whatcott CJ, Posner RG, Von Hoff DD, Han H. (2012) Desmoplasia and chemoresistance in pancreatic cancer. In: Pancreatic Cancer and Tumor Microenvironment. Grippo PJ, Munshi HG (eds.). Transworld Research Network, Trivandrum, India. Chapter 8 (https://doi.org/www.ncbi.nlm.nih.gov/pubmed/22876390).Google Scholar
- 59.Daley D, et al. (2016) yS T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation. 166:1485–99, e15.Google Scholar
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.
The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)